Do Not Switch to Nitrofurantoin (Macrobid)
You should not switch from ertapenem to nitrofurantoin in this patient with ESBL E. coli and E. faecalis urinary tract infection. Nitrofurantoin is FDA-approved only for uncomplicated cystitis and explicitly lacks the tissue distribution needed for complicated infections or polymicrobial UTIs 1.
Critical Limitations of Nitrofurantoin in This Case
FDA-Approved Indication Mismatch
The FDA label for Macrobid is unequivocal: it is indicated only for acute uncomplicated cystitis caused by susceptible E. coli or Staphylococcus saprophyticus 1. The label explicitly warns that "nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections" and that "many patients who are treated with Macrobid are predisposed to persistence or reappearance of bacteriuria" 1.
Polymicrobial Infection Problem
Your patient has two pathogens: ESBL E. coli and E. faecalis. While nitrofurantoin shows activity against both organisms in vitro 1, the FDA specifically states it is "not indicated for the treatment of pyelonephritis or perinephric abscesses" 1. The presence of E. faecalis suggests this may be a complicated UTI, not simple cystitis.
Clinical Context Matters
The fact that this patient is on IV ertapenem (rather than oral therapy) strongly suggests:
- Complicated UTI (not uncomplicated cystitis)
- Inability to take oral medications initially
- Systemic illness requiring parenteral therapy
- Possible upper tract involvement
When Nitrofurantoin IS Appropriate for ESBL E. coli
Nitrofurantoin can be highly effective for uncomplicated lower urinary tract infections caused by ESBL-producing E. coli, with sensitivity rates of 83-96% 2, 3, 4. The 2024 EAU guidelines list nitrofurantoin as first-line therapy for uncomplicated cystitis with a 5-day course 5. Research demonstrates clinical success rates of 69% and microbiological success of 68% for ESBL E. coli-related lower UTI 3.
However, these studies specifically excluded patients with:
- Fever or leukocytosis
- Upper tract involvement
- Complicated UTI features
Appropriate De-escalation Strategy
If This Is Uncomplicated Cystitis
If your patient has:
- No fever, flank pain, or systemic symptoms
- Normal renal function (CrCl >60 mL/min)
- No anatomic abnormalities
- Symptoms limited to dysuria/frequency/urgency
Then consider oral step-down to:
- Fosfomycin 3g single dose (97-98% sensitivity to ESBL E. coli) 4, 6
- Pivmecillinam 400mg TID for 3-5 days (85% sensitivity) 6
- Nitrofurantoin 100mg BID for 5 days (if truly uncomplicated) 5
If This Is Complicated UTI or Pyelonephritis
Continue ertapenem or switch to another agent with adequate tissue distribution. The 2024 JAMA guidelines recommend carbapenems for empirical therapy in patients with risk factors for multidrug resistance 7. For ESBL-producing organisms, ertapenem remains appropriate with typical dosing of 1g IV daily 8.
Common Pitfalls to Avoid
- Don't assume all UTIs are uncomplicated - The need for IV therapy suggests otherwise
- Don't ignore the polymicrobial nature - E. faecalis co-infection may indicate complicated disease
- Don't rely on nitrofurantoin for tissue penetration - It achieves therapeutic levels only in urine 1
- Don't switch based solely on susceptibility data - Clinical syndrome determines appropriate therapy
Recommended Approach
Determine the clinical syndrome first:
- Review fever curve, vital signs, and symptoms
- Assess for flank pain, costovertebral angle tenderness
- Check for urologic abnormalities, catheter use, or recent instrumentation
- Evaluate renal function
If uncomplicated cystitis: Consider oral step-down to fosfomycin or pivmecillinam (preferred over nitrofurantoin given polymicrobial infection)
If complicated UTI/pyelonephritis: Complete 7-14 days of ertapenem depending on clinical response 7, 5
The presence of ESBL E. coli with E. faecalis and the initial need for IV therapy strongly suggest this is NOT a candidate for nitrofurantoin therapy.